Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05897320 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of Eptinezumab in Pediatric Participants With Episodic Migraine

Study acronym: PROSPECT-1
StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study sites: 64 to 62v31
  2. Study sites: 65 to 64v30
  3. Site details revised at 2 of 65 sitesv29
  4. Study sites revised (65)v28 See this version in full on ClinicalTrials.gov ↗
  5. Study sites: 63 to 65v27
Show 25 earlier versionsHide 25 earlier versions
  1. Re-verified, no change to tracked fieldsv26
  2. Study sites revised (63)v25 See this version in full on ClinicalTrials.gov ↗
  3. Site details revised at 2 of 63 sitesv24
  4. Study sites: 62 to 63 Primary completion date: May 5, 2027 to Jul 6, 2027 · Completion date: Jun 30, 2027 to Aug 31, 2027v23 Show 2 more changesShow less
    • Primary completion date: May 5, 2027 to Jul 6, 2027
    • Completion date: Jun 30, 2027 to Aug 31, 2027
  5. Study sites: 60 to 62v22
  6. Study sites revised (60)v21 See this version in full on ClinicalTrials.gov ↗
  7. Study sites: 58 to 60v20
  8. Study sites: 54 to 58v19
  9. Study sites: 51 to 54v18
  10. Study sites: 50 to 51v17
  11. Primary completion date: Oct 31, 2024 to May 5, 2027 Study sites: 48 to 50 · Completion date: Oct 31, 2024 to Jun 30, 2027v16 Show 2 more changesShow less
    • Study sites: 48 to 50
    • Completion date: Oct 31, 2024 to Jun 30, 2027
  12. Study sites: 46 to 48v15
  13. Study sites: 45 to 46v14
  14. Study sites: 44 to 45v13
  15. Study sites: 41 to 44v12
  16. Study sites: 28 to 41v11
  17. Study sites: 27 to 28v10
  18. Study sites: 26 to 27v9
  19. Study sites: 18 to 26v8
  20. Study sites: 11 to 18v7
  21. Study sites: 5 to 11v6
  22. Study sites: 3 to 5v5
  23. Study sites: 2 to 3v4
  24. Study sites: 1 to 2v3
  25. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 1 · Start date changed from estimate of Jun 9, 2023 to Jun 8, 2023v2 Show 2 more changesShow less
    • Study sites: 0 to 1
    • Start date changed from estimate of Jun 9, 2023 to Jun 8, 2023
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
H. Lundbeck A/S
20 trials monitored
See 1 trial at risk
Migraine
467 trials monitored
See 24 trials at risk
The main goal of this trial is to learn whether eptinezumab helps reduce the number of days with episodic migraine in pediatric participants.
Trial Details
NCT Number NCT05897320
Lead Sponsor H. Lundbeck A/S
Conditions Episodic Migraine
Enrollment 315 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov